Advertisement

Cloning, Expression, and Purification of Monoclonal Antibodies in scFv-Fc Format

  • Jiahui Yang
  • Christoph RaderEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 901)

Abstract

This protocol describes the generation of monoclonal antibodies in single-chain variable fragment (scFv)-Fc format. It includes the cloning of the scFv-Fc expression cassette into a mammalian expression vector followed by transient transfection of mammalian cells and purification by protein A affinity chromatography. The protocol is intended for applications in basic and preclinical research that require rapid access to milligram amounts of protein.

Key words

Monoclonal antibodies scFv-Fc format Hemagglutinin tag FreeStyle 293F cells Protein A affinity chromatography 

Notes

Acknowledgments

This work was supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health. We thank Marko Modric for comments.

References

  1. 1.
    Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23:1126–1136PubMedCrossRefGoogle Scholar
  2. 2.
    Kontermann RE (2010) Alternative antibody formats. Curr Opin Mol Ther 12:176–183PubMedGoogle Scholar
  3. 3.
    Shu L, Qi CF, Schlom J et al (1993) Secretion of a single-gene-encoded immunoglobulin from myeloma cells. Proc Natl Acad Sci USA 90:7995–7999PubMedCrossRefGoogle Scholar
  4. 4.
    Zhao X, Lapalombella R, Joshi T et al (2007) Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 11:2569–2577CrossRefGoogle Scholar
  5. 5.
    Robak T, Robak P, Smolewski P (2009) TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs 10:1383–1390PubMedGoogle Scholar
  6. 6.
    Hayden-Ledbetter MS, Cerveny CG, Espling E et al (2009) CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin Cancer Res 15:2739–2746PubMedCrossRefGoogle Scholar
  7. 7.
    Rubbert-Roth A (2010) TRU-015, a fusion protein derived from an anti-CD20 antibody, for the treatment of rheumatoid arthritis. Curr Opin Mol Ther 12:115–123PubMedGoogle Scholar
  8. 8.
    Brocks B, Rode HJ, Klein M et al (1997) A TNF receptor antagonistic scFv, which is not secreted in mammalian cells, is expressed as a soluble mono- and bivalent scFv derivative in insect cells. Immunotechnology 3:173–184PubMedCrossRefGoogle Scholar
  9. 9.
    Powers DB, Amersdorfer P, Poul M et al (2001) Expression of single-chain Fv-Fc fusions in Pichia pastoris. J Immunol Methods 251:123–135PubMedCrossRefGoogle Scholar
  10. 10.
    Van Droogenbroeck B, Cao J, Stadlmann J et al (2007) Aberrant localization and underglycosylation of highly accumulating single-chain Fv-Fc antibodies in transgenic Arabidopsis seeds. Proc Natl Acad Sci USA 104:1430–1435PubMedCrossRefGoogle Scholar
  11. 11.
    Cao P, Zhang S, Gong Z et al (2006) Development of a compact anti-BAFF antibody in Escherichia coli. Appl Microbiol Biotechnol 73:151–157PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Experimental Transplantation and Immunology BranchCenter for Cancer Research, National Cancer Institute, National Institutes of HealthBethesdaUSA
  2. 2.Department of Cancer Biology and Department of Molecular TherapeuticsThe Scripps Research InstituteScripps Florida JupiterUSA

Personalised recommendations